DICLOXACILLIN SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H16Cl2N3O5S.Na.H2O
Molecular Weight	510.323
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.[Na+].CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O)C(=NO1)C4=C(Cl)C=CC=C4Cl

InChI

InChIKey=SIGZQNJITOWQEF-VICXVTCVSA-M

InChI=1S/C19H17Cl2N3O5S.Na.H2O/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24;;/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28);;1H2/q;+1;/p-1/t13-,14+,17-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H17Cl2N3O5S
Molecular Weight	470.326
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/pro/dicloxacillin.html
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00485 | https://www.ncbi.nlm.nih.gov/pubmed/6559051 | https://www.ncbi.nlm.nih.gov/pubmed/3923593 | https://www.ncbi.nlm.nih.gov/pubmed/20308386

Dicloxacillin sodium USP is a semisynthetic antibiotic substance which resists destruction by the enzyme penicillinase (beta-lactamase). It is monosodium (2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5-methyl-4- isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane-2-carboxylate monohydrate. Like other β-lactam antibiotics, dicloxacillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. Dicloxacillin is administered orally via capsule form or powder for reconstitution.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Penicillin-binding protein 31 Target ID: CHEMBL2362973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7447421	Inhibitor 8504
peptidoglycan biosynthetic process 6 Target ID: GO:0009252 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6559051	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Infections caused by penicillinase-producing staphylococci 8 Sources: https://www.drugs.com/pro/dicloxacillin.html	Curative	Approved 8583	PATHOCIL Approved Use Indications and Usage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dicloxacillin sodium capsules USP and other antibacterial drugs, Dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing). Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. Launch Date 1968
Bronchitis 51 Sources: https://www.drugs.com/pro/dicloxacillin.html	Curative	Approved 8583	PATHOCIL Approved Use Indications and Usage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dicloxacillin sodium capsules USP and other antibacterial drugs, Dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing). Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. Launch Date 1968
Pneumonia 91 Sources: https://www.drugs.com/dosage/dicloxacillin.html	Curative	Approved 8583	PATHOCIL Approved Use Indications and Usage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dicloxacillin sodium capsules USP and other antibacterial drugs, Dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing). Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. Launch Date 1968

C_max

Value	Dose	Analyte	Population
17 μg/mL DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=65c3e99b-ec77-416c-ad70-596d6f0a9c31&type=display	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
13.62 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	0.25 g single, oral dose: 0.25 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
24.28 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
45.02 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
79.97 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
32.78 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	0.25 g single, oral dose: 0.25 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
62.43 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
110.93 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
207.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.7 h DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=65c3e99b-ec77-416c-ad70-596d6f0a9c31&type=display	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
1.38 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	0.25 g single, oral dose: 0.25 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26527863	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	DICLOXACILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
3% DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=65c3e99b-ec77-416c-ad70-596d6f0a9c31&type=display	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		DICLOXACILLIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
25 mg/kg multiple, oral Dose: 25 mg/kg Route: oral Route: multiple Dose: 25 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/8396081/	unhealthy, 2-12 Health Status: unhealthy Age Group: 2-12 Sources: https://pubmed.ncbi.nlm.nih.gov/8396081/	Other AEs: Abdominal pain, Vomiting... Other AEs: Abdominal pain (mild, 1 patient) Vomiting (mild, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/8396081/
2 g single, oral Dose: 2 g Route: oral Route: single Dose: 2 g Sources: https://pubmed.ncbi.nlm.nih.gov/26527863/	healthy, 22.2 Health Status: healthy Age Group: 22.2 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26527863/	Sources: https://pubmed.ncbi.nlm.nih.gov/26527863/
0.5 g 4 times / day single, oral Dose: 0.5 g, 4 times / day Route: oral Route: single Dose: 0.5 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26527863/	healthy, 22.3 Health Status: healthy Age Group: 22.3 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26527863/	Sources: https://pubmed.ncbi.nlm.nih.gov/26527863/

AEs

AE	Significance	Dose	Population
Abdominal pain	mild, 1 patient	25 mg/kg multiple, oral Dose: 25 mg/kg Route: oral Route: multiple Dose: 25 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/8396081/	unhealthy, 2-12 Health Status: unhealthy Age Group: 2-12 Sources: https://pubmed.ncbi.nlm.nih.gov/8396081/
Vomiting	mild, 1 patient	25 mg/kg multiple, oral Dose: 25 mg/kg Route: oral Route: multiple Dose: 25 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/8396081/	unhealthy, 2-12 Health Status: unhealthy Age Group: 2-12 Sources: https://pubmed.ncbi.nlm.nih.gov/8396081/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087	inducer 440	inducer 109

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 BSEP 550	P-gp 2052	CYP2C19 329 CYP1A2 832

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1592/phco.28.7.883 Page: abstract	no
CYP1A2 2333	inducer 1966 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13467 Page: 516.0	unlikely
CYP2D6 2546	inducer 1966 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13467 Page: 517.0	unlikely
BSEP 554	inhibitor 4027 Sources: https://pubs.rsc.org/no/content/articlelanding/2017/mb/c6mb00744a/unauth#!divAbstract Page: 20.0	yes
CYP2C9 2497	inducer 1966 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13467 Page: 516.0	yes
CYP3A4 2633	inducer 1966 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13467 Page: 516.0	yes
CYP2C19 2141	inducer 1966 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13467 Page: 516.0	yes	yes (co-administration study) Comment: dicloxacillin decreased omeprazole AUC 67%, Cmax 60% Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13467 Page: 516.0

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://link.springer.com/article/10.1023/A:1015191511817 Page: 457.0	yes		yes (co-administration study) Comment: ketoconazole decreased flux of dicloxacillin Sources: https://link.springer.com/article/10.1023/A:1015191511817 Page: 457.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4511	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4511
ChemicalBook	CB6704937	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6704937
ZINC	ZINC000003978006	http://zinc15.docking.org/substances/ZINC000003978006

PubMed

Title	Date	PubMed
Effect of dicloxacillin, oxacillin, and nafcillin upon staphylococcal population and rate of healing of soft-tissue lesions.	1966	5985303
Clinical, laboratory, and pharmacological studies of dicloxacillin.	1966	5982342
Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study.	2002	12195877
In vitro susceptibility of Staphylococcus aureus towards amoxycillin-clavulanic acid, penicillin-clavulanic acid, dicloxacillin and cefuroxime.	2002 Aug	12390414
[Staphylococcus aureus infections--the clinical picture and treatment].	2002 Aug 5	12362608
Compatibility between active components of a commercial drug.	2002 Oct	12420879
Eruption on the face. Bulla formation and crusting on the forehead and nose can be easily treated.	2002 Sep	12271824
PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.	2002 Sep 26	12323078
Dicloxacillin: a higher risk than cloxacillin for infusion phlebitis.	2003	12953952
[Long-term antibiotic suppressive therapy for an infected thoracic aorta graft].	2003 Aug 28	14508548
High-performance thin-layer chromatography-bioautography for multiple antibiotic residues in cow's milk.	2003 Feb 5	12505779
Residues of beta-lactam antibiotics in bovine milk: confirmatory analysis by liquid chromatography tandem mass spectrometry after microbial assay screening.	2003 Jun	12881125
Large-volume sample stacking combined with separation by 2-hydroxypropyl-beta-cyclodextrin for analysis of isoxyzolylpenicillins by capillary electrophoresis.	2003 Sep	12973814
Necrotizing surgical site infection after tension-free vaginal tape.	2004 Dec	15572489
Application of ion-exchange cartridge clean-up in food analysis. VI. Determination of six penicillins in bovine tissues by liquid chromatography-electrospray ionization tandem mass spectrometry.	2004 Jul 9	15296394
Liquid chromatographic assay for dicloxacillin in plasma.	2004 Jun 15	15135112
Community-acquired methicillin-resistant Staphylococcus aureus among military recruits.	2004 May	15200838
Cases from the aerospace medicine residents' teaching file: furunculosis.	2004 Nov	15559005
Interactions of two amphiphilic penicillins with myoglobin in aqueous buffered solutions: a thermodynamic and spectroscopy study.	2004 Nov-Dec	15530034
Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002.	2004 Sep	15498166
Laser-mediated photodynamic therapy of actinic cheilitis.	2004 Sep-Oct	15552607
Rapidly growing mycobacteria in King Chulalongkorn Memorial Hospital and review of the literature in Thailand.	2005 Aug	16404850
Development of a novel and automated fluorescent immunoassay for the analysis of beta-lactam antibiotics.	2005 Aug 24	16104778
Diagnosis and management of staphylococcal infections of vascular grafts and stents.	2005 Dec	16271063
Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators.	2005 Dec	16271062
Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus.	2005 Dec	16271060
[Treatment of chronic bovine endometritis and factors for treatment success].	2005 Jan	15714870
Confirmatory and quantitative analysis of beta-lactam antibiotics in bovine kidney tissue by dispersive solid-phase extraction and liquid chromatography-tandem mass spectrometry.	2005 Mar 1	15732933
Influence of sub-inhibitory concentrations of antimicrobial agents on biofilm formation in indwelling medical devices.	2005 Nov	16353125
Cheilitis glandularis in an African-American woman: response to antibiotic therapy.	2005 Nov-Dec	16276162
Clonal spread of Staphylococcus aureus with reduced susceptibility to oxacillin in a dermatological hospital unit.	2006	16710581
Influence of SDS and two anionic hydrotropes on the micellized state of the triblock copolymer E71G7E71.	2006 Apr 15	16242706
Positive effect of natural and negatively charged cyclodextrins on the stabilization of penicillins towards beta-lactamase degradation due to inclusion and external guest-host association. An NMR and MS study.	2006 Apr 7	16557318
Pseudomonas aeruginosa otochondritis complicating localized cutaneous leishmaniasis: prevention of mutilation by early antibiotic therapy.	2006 Aug	16896131
Placental transfer of antibiotics administered to the mother: a review.	2006 Feb	16502764
Recurrent staphylococcal conjunctivitis associated with facial impetigo contagiosa.	2006 Jan	16386997
Efficient approach for the reliable quantification and confirmation of antibiotics in water using on-line solid-phase extraction liquid chromatography/tandem mass spectrometry.	2006 Jan 20	16309690
Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.	2006 Jan 6	16398929
Surface and bulk properties of two anionic amphiphilic penicillins in a selective solvent.	2006 Jul 20	16836332
Molecular engineering of fluorescent penicillins for molecularly imprinted polymer assays.	2006 Mar 15	16536441
Spectrophotometric determination of flucloxacillin and dicloxacillin in pure and dosage forms.	2006 May 1	16431153
In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains.	2006 Oct 12	17034644
Determination of antimicrobials in sludge from infiltration basins at two artificial recharge plants by pressurized liquid extraction-liquid chromatography-tandem mass spectrometry.	2006 Oct 13	16822516
Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients.	2006 Sep 11	16965625
Antibiotic resistance of lactic acid bacteria and Bifidobacterium spp. isolated from dairy and pharmaceutical products.	2007 Apr 1	17198739
Direct extraction of penicillin G and derivatives from aqueous samples using a stoichiometrically imprinted polymer.	2007 Jan 15	17222039
Heterogeneity of human adipose blood flow.	2007 Jan 20	17239252
Oral beta-lactams applied to uncomplicated infections of skin and skin structures.	2007 Mar	17292581
Characterisation of KLUA-9, a beta-lactamase from extended-spectrum cephalosporin-susceptible Kluyvera ascorbata, and genetic organisation of bla(KLUA-9).	2007 Mar	17196371
Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.	2007 Mar 12	17125952

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Bronchitis: 250 to 500 mg orally every 6 hours for 10 days, depending on the nature and severity of the infection. Usual Adult Dose for Pneumonia: 500 mg orally every 6 hours for up to 21 days, depending on the nature and severity of the infection.

Route of Administration: Oral

In Vitro Use Guide

Bacteria strains ATCC 25923 and E19977 at a density of 10-6 Colony-forming unit /ml were exposed to Dicloxacillin concentrations that varied over a wide range (to obtain a full description of the pharmacological response), and quantification of the numbers of Colony-forming unit was performed after 5 and 24 h of incubation. The MICs of Dicloxacillin at pH 7.4 was 0.125 mg/liter (ATCC 25923) and 0.5 mg/liter (E19977).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:55:54 GMT 2025` Edited by `admin` on `Mon Mar 31 17:55:54 GMT 2025`
Record UNII	4HZT2V9KX0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DICLOXACILLIN SODIUM

Official Name

English

DICLOXACILLIN SODIUM MONOHYDRATE

Preferred Name

English

DICLOXACILLINUM NATRICUM [WHO-IP LATIN]

Common Name

English

P-1011

Code

English

DICLOXACILLIN SODIUM [USP-RS]

Common Name

English

DICLOXACILLIN SODIUM [ORANGE BOOK]

Common Name

English

DICLOXACILLIN SODIUM [VANDF]

Common Name

English

DICLOXACILLIN SODIUM SALT MONOHYDRATE

Common Name

English

SODIUM DICLOXACILLIN MONOHYDRATE

Common Name

English

NSC-756726

Code

English

DICLOXACILLIN SODIUM [USP IMPURITY]

Common Name

English

DICLOXACILLIN SODIUM [WHO-IP]

Common Name

English

DICLOXACILLIN SODIUM HYDRATE [JAN]

Common Name

English

DICLOXACILLIN SODIUM [USAN]

Common Name

English

DICLOXACILLIN SODIUM SALT MONOHYDRATE [MI]

Common Name

English

DYNAPEN

Brand Name

English

DYCILL

Brand Name

English

Monosodium (2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate monohydrate

Systematic Name

English

DICLOXACILLIN SODIUM [MART.]

Common Name

English

DICLOXACILLIN SODIUM MONOHYDRATE [GREEN BOOK]

Common Name

English

SODIUM DICLOXACILLIN

Common Name

English

DICLOXACILLIN SODIUM [USP MONOGRAPH]

Common Name

English

Dicloxacillin sodium monohydrate [WHO-DD]

Common Name

English

DICLOXACILLIN SODIUM [EP MONOGRAPH]

Common Name

English

4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-(((3-(2,6-DICHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL)CARBONYL)AMINO)-3,3-DIMETHYL-7-OXO-, MONOSODIUM SALT, MONOHYDRATE, (2S-(2.ALPHA.,5.ALPHA.,6.BETA.))-

Common Name

English

PATHOCIL

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1500